Safety and efficacy of eculizumab in the prevention of antibody‐mediated rejection in living‐donor kidney transplant recipients requiring desensitization therapy: A randomized trial

We report results of a phase 2, randomized, multicenter, open‐label, two‐arm study evaluating the safety and efficacy of eculizumab in preventing acute antibody‐mediated rejection (AMR) in sensitized recipients of living‐donor kidney transplants requiring pretransplant desensitization (NCT01399593)....

Descripción completa

Detalles Bibliográficos
Autores principales: Marks, William H., Mamode, Nizam, Montgomery, Robert A., Stegall, Mark D., Ratner, Lloyd E., Cornell, Lynn D., Rowshani, Ajda T., Colvin, Robert B., Dain, Bradley, Boice, Judith A., Glotz, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790671/
https://www.ncbi.nlm.nih.gov/pubmed/30887675
http://dx.doi.org/10.1111/ajt.15364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790671/
https://www.ncbi.nlm.nih.gov/pubmed/30887675
http://dx.doi.org/10.1111/ajt.15364

Ejemplares similares